Tagged with DIA

Belgium Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its European Clinical Trial Services (ELECTS) division, and his aim to reach 200,000 patients in Belgium with Lilly treatments before the…

MENA Amira Younes of AbbVie UAE examines how the COVID-19 pandemic highlighted the need for new ways of thinking about delivering regulatory effectiveness and efficiency in the region, and for flexibility from all stakeholders to ensure that therapies continue to reach patients in a timely manner.   Most countries in the…

Ukraine Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection in clinical trials in Ukraine during wartime.   The ongoing war places unprecedented pressure on the healthcare system and clinical…

USA After considerable government pressure to reduce insulin costs in the US, Eli Lilly recently slashed its prices by as much as 70 percent, followed by competitors Novo Nordisk and Sanofi. While these steps to make insulin more affordable, together with the US Medicare insulin price cap that came into effect…

Ukraine The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Here, Chieko Kurihara of Kanagawa Dental University, Japan; Victoriia Dobrova of Ukraine’s National University of Pharmacy; Francis P. Crawley of the Good…

Ukraine The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Anina Adelfio of the Association of Clinical Research Organizations (ACRO) looks back on an extremely challenging two years for the clinical trial…

India The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and the Cipla manufacturing site under FDA scrutiny.   Dr. Reddy’s to buy Mayne Pharma’s US business for USD 105 million…

Africa As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam from Leslie Sam and Associates, Jayesh Pandit, a Patient Safety Advocate from Kenya, Helen Ndagije of the Uganda National Drug…

Japan Writing in the February 2023 edition of DIA’s Global Forum magazine, Yumi Wakabayashi of Janssen, Takahiro Horimatsu from the Institute for Advancement of Clinical and Translational Science at Kyoto University, Hiroshi Asai of Astellas, Yasuhiro Himeno from the Government of Japan’s Cabinet Office, and Hiroyuki Taruno of the Cancer Institute…

India The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA warning and the lab partnership between Sai Life Sciences and Schrödinger.   WHO recommends not using Marion Biotech cough syrups…

Africa Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant Eli Lilly and Egyptian group EVA Pharma. The agreement will allow Lilly products to be manufactured in, and for, the…

Europe Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on Health Technology Assessment.   In December 2021, the European Commission (EC) adopted the Regulation on Health Technology Assessment (EU HTA…